NTRK (Neurotrophic receptor tyrosine kinase)

P=N/A, N=42, Recruiting, Cantonal Hospital of St. Gallen

P2, N=60, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris

Somatic PGVs in potentially targetable pathways were found in 72% of ATC tumors. Given the aggressiveness of ATC and the limited efficacy of current treatments, these findings support the rationale for biomarker-driven basket trials investigating the efficacy of targeted therapies in this population.

P2, N=137, Completed, Daiichi Sankyo | Active, not recruiting --> Completed

Multiple rare thyroid malignancies may present indistinguishably from ATC, emphasizing the need for meticulous histopathologic and molecular evaluation.

Although tissue-agnostic therapy has expanded the reach of precision oncology, thoracic and H&N cancers remain underrepresented in registrational evidence. Most approvals rely on single-arm basket studies with small, heterogeneous subsets that preclude histology-specific conclusions. Future research should prioritize histology-enriched trial designs, standardized molecular diagnostics, and real-world validation to establish reliable, equitable standards of care for these underrepresented malignancies.

P1/2, N=111, Not yet recruiting, Biocity Biopharmaceutics Co., Ltd.

In addition, epithelioid fibrous histiocytoma has been reassigned to the family of tumors of uncertain differentiation. This review summarizes the key updates and newly recognized entities in the chapter on cutaneous soft tissue tumors in the 5th edition of the WHO classification of skin tumors, emphasizing their clinicopathological and molecular implications.

P1/2, N=132, Recruiting, Mayo Clinic | N=36 --> 132 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2025 --> Mar 2028

There are several challenges including the lack of randomized perioperative trials, heterogeneity in pathological response assessment, and uncertainty regarding the reliability of surrogate endpoints. With the increasing integration of next-generation sequencing into the standard diagnostic workup of early-stage NSCLC, biomarker-directed perioperative strategies supported by prospective clinical trials enriched for specific genotypes are critical to achieving sustained clinical outcomes in these patient subgroups with rare targetable alterations.

P1/2, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Jun 2027

P=N/A, N=833, Completed, AstraZeneca | Enrolling by invitation --> Completed